Project Grant R21AI193182

Award Date 7/16/25
Completion Date 6/30/27
Dollars Obligated $440K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This $151,040 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the regulatory role of the small regulatory RNA BECO on essential virulence factors in the pathogen Pseudomonas aeruginosa. The research aims to determine how BECO controls the expression of the Type III Secretion System and pyochelin biosynthesis genes, which are critical for P....
This federal Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to overcome them. The award recipient, The University of Texas Southwestern Medical Center, will investigate resistance to these novel antibacterial compounds called...
This Project Grant award of $868,776.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize a novel post-transcriptional regulator in the opportunistic pathogen Pseudomonas aeruginosa. The key objectives are to: Identify the direct regulatory targets of the RNA-binding protein PhaF under standard lab conditions, infection-relevant conditions, and in clinical isolates to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,388,838 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation For The State University Of New York (RF SUNY) to optimize phage cocktail regimens for treating extensively drug-resistant Pseudomonas aeruginosa. The project aims to: 1) develop a quantification assay for the phage cocktail, 2) identify optimal phage combinations and administration patterns...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $205,000 to The Trustees of Princeton University to conduct research examining the influence of chromosome copy number on Pseudomonas aeruginosa persisters to fluoroquinolone antibiotics. The research aims to fill knowledge gaps in understanding persistence to this antibiotic class in this opportunistic pathogen that...
The Scripps Research Institute was awarded a $779,915 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The 5-year grant, effective May 5, 2025, will support research to investigate the chromatin remodeling functions of polyphosphate condensates in the opportunistic pathogen Pseudomonas aeruginosa. The project aims to define the relationship between polyphosphate, a stress-responsive...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $453,629 to Yale University to conduct research on the cell surface of the opportunistic pathogen Pseudomonas aeruginosa. The project, titled "Phage-Seq Phenotyping of the Pseudomonas aeruginosa Surface-ome", aims to develop a high-throughput technology called "Phage-Seq" that can survey bacterial cell surfaces and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,144,714 to the University of Illinois to conduct research aimed at discovering novel antibiotics for gram-negative pathogens. The primary goals are to identify physicochemical traits that allow antibiotics to evade efflux pumps in E. coli, P. aeruginosa, and A. baumannii, and then apply this knowledge to develop at...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program, provides $430,760 to the University of Pittsburgh to conduct research on improving host defense against the deadly Gram-negative bacterium, Pseudomonas aeruginosa. The key objectives are to: 1) Determine the role of the CXCR4 chemokine receptor and galectin-3 protein in the protective function of lung...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $451,000.00 to The Trustees of Princeton University to conduct research aimed at identifying new antimicrobial targets in Gram-negative bacterial pathogens. The key products of this 2-year project involve: 1) Identifying a small molecule inhibitor of methionine synthase that demonstrates chemical synthetic lethality...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $439,896 to William Marsh Rice University to conduct research on developing pyocin-based treatments for multidrug-resistant Pseudomonas aeruginosa infections. The key objectives are to: 1) Comprehensively evaluate a panel of R pyocins from different subtypes to identify those with the widest killing spectrum against P. aeruginosa; 2) Examine the relationships between LPS mutations, pyocin sensitivity, and pyocin production; and 3) Produce high-purity recombinant pyocins and test their activity and toxicity. This research aims to provide a thorough evaluation of the clinical potential of R pyocins and identify key LPS proteins that could further expand their killing range against this serious bacterial threat.

Generated 8/5/25, 2:50 AM